# A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

> **NCT02972840** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Acerta Pharma BV** · enrollment: 635 (actual)

## Conditions studied

- Lymphoma, Mantle Cell

## Interventions

- **DRUG:** Acalabrutinib
- **DRUG:** Bendamustine
- **DRUG:** Rituximab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02972840
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-04-05
- **Primary completion:** 2027-02-15
- **Final completion:** 2027-02-15
- **Target enrollment:** 635 (ACTUAL)
- **Last updated:** 2026-02-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02972840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02972840, "A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT02972840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*